Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341534 | 0.79 | MAPT (0.37) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL28549550 | 0.79 | ACHE (0.40) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL28570427 | 0.76 | ACHE (0.46) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL28562469 | 0.74 | ACHE (0.38) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL28553031 | 0.73 | ACHE (0.51) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL15517522 | 0.69 | SLC29A1 (0.35) | ALDH1A1MAPTRECQLERBB2 | |
| SCHEMBL5179874 | 0.66 | ERBB2 (0.41) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL8756842 | 0.64 | ALDH1A1 (0.35) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL27528950 | 0.62 | ACHE (0.53) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL2027891 | 0.61 | MAOA (0.48) | MEN1ALDH1A1MAPTHPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398676-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| US-20180140575-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2018-05-24 | — | — | US | disclosed |
| US-9907784-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20150231113-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-9029569-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| EP-1951213-B1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LTD (GB) | 2012-11-14 | — | — | EP | disclosed |
| EP-2258430-A2 | 5-(Aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide and its use in medicine | Morvus Technology Ltd. (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | MEN1 4352/4885ALDH1A1 78/4885MAPT 3157/4885 |
| US-10398676-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | DERA, HOGA1, ALDOA | MEN1 4352/4885ALDH1A1 78/4885MAPT 3157/4885 |
| US-20180140575-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | MEN1 4352/4885ALDH1A1 78/4885MAPT 3157/4885 |
| US-20150231113-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | MEN1 4352/4885ALDH1A1 78/4885MAPT 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.